Abstract
The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.
| Original language | English |
|---|---|
| Journal | Transplant Immunology |
| DOIs | |
| Publication status | Accepted/In press - 2017 Mar 22 |
Fingerprint
Keywords
- Bone marrow transplantation
- CCR5
- Graft-versus-host disease
- Single nucleotide variation
- Unrelated donor
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Transplantation
Cite this
The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. / Horio, Tomohiro; Mizuno, Shohei; Uchino, Kaori; Mizutani, Motonori; Hanamura, Ichiro; Espinoza, J. Luis; Onizuka, Makoto; Kashiwase, Koichi; Morishima, Yasuo; Fukuda, Takahiro; Kodera, Yoshihisa; Doki, Noriko; Miyamura, Koichi; Mori, Takehiko; Takami, Akiyoshi.
In: Transplant Immunology, 22.03.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation
AU - Horio, Tomohiro
AU - Mizuno, Shohei
AU - Uchino, Kaori
AU - Mizutani, Motonori
AU - Hanamura, Ichiro
AU - Espinoza, J. Luis
AU - Onizuka, Makoto
AU - Kashiwase, Koichi
AU - Morishima, Yasuo
AU - Fukuda, Takahiro
AU - Kodera, Yoshihisa
AU - Doki, Noriko
AU - Miyamura, Koichi
AU - Mori, Takehiko
AU - Takami, Akiyoshi
PY - 2017/3/22
Y1 - 2017/3/22
N2 - The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.
AB - The chemokine receptor CCR5 plays roles in the trafficking of effector cells towards the site of inflammation. We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A. >. G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. A multivariate analysis showed that the recipient CCR5 -2086A/A genotype was significantly associated with a lower relapse rate but not with the development of graft-versus-host disease (GVHD) or transplant-related mortality, thereby resulting in better disease-free and overall survival rates than other variations. The donor CCR5 -2086A/A genotype was associated with a lower incidence of grades 3-4 acute GVHD, which did not improve the survival outcomes. These findings suggest that the recipient CCR5 -2086A/A genotype affects the induction of the graft-versus-tumor effect without augmenting the development of GVHD. CCR5 genotyping in transplant recipients may therefore be a useful tool for evaluating pretransplantation risks.
KW - Bone marrow transplantation
KW - CCR5
KW - Graft-versus-host disease
KW - Single nucleotide variation
KW - Unrelated donor
UR - http://www.scopus.com/inward/record.url?scp=85019076279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019076279&partnerID=8YFLogxK
U2 - 10.1016/j.trim.2017.05.003
DO - 10.1016/j.trim.2017.05.003
M3 - Article
JO - Transplant Immunology
JF - Transplant Immunology
SN - 0966-3274
ER -